Global Peptide Therapeutics Market Dosage Price & Clinical Trials Insight 2024

Publish Date:- May-2018       No Of Pages (1250)

Electronic Access - Single User License $3000 Buy Now
CD-ROM Mail Delivery $3600Buy Now
Hard Copy Mail Delivery $4400 Buy Now
Electronic Access - Multi-User License $5400 Buy Now


“Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024” Report Highlight:

 

  • Global Peptide Therapeutics Market Opportunity: More Than US$ 50 Billion
  • Cost Analysis & Market Insight into its Application
  • Dosage & Sales Analysis of Key Drugs
  • Global Peptide Drug Clinical Pipeline: 612 Drugs
  • Peptide Drug Application  by Indication
  • Global Peptide Pipeline by Indication, Company & Phase
  • Marketed Peptide Drugs: 101 Drugs
  • Clinical Trials Insight by Peptide Classification

 

Peptide based therapeutics are currently experiencing a renaissance in the global market with collective sales of more than US$ 20 Billion in 2017. Therapeutics such as Lantus, from Sanofi has recently managed to become a blockbuster peptide therapeutic with record sales of over US$ 8 Billion in 2017. Overall, the global peptide therapeutics market is expected to surpass US$ 50 Billion by 2024 from less than US$ 30 Billion in 2018. The overall market growth will be driven by the increasing research and development expenditure by pharmaceutical organizations along with rapid entry of multiple peptide based drug in the market. 

As of 2018, more than 100 approved peptide therapeutics for various clinical indications are commercially available in the global market. Additionally, a robust clinical pipeline currently has more than 100 type of therapeutics in late stage of clinical development with more than 200 types of therapeutics in pre-clinical stage.  

Epidemic increase in clinical indications such as obesity, type II diabetes along with complex disease like cancer are key driving factors of the global peptide therapeutics market. Involvement of global pharmaceutical giants in mass production of peptide therapeutics and impressive investment in their research and development in segments like oncology, genetic disorders, rare disease and autoimmune disease is further bound to make it one of the most active and lucrative market in the future.

Owing to the high prevalence of lifestyle disorders like type II diabetes and obesity, the US currently leads the global peptide therapeutics market by a significant margin; followed by the European Union. However, with the alarming increase in patient base, the Asia-Pacific region is anticipated to emerge as one of the fastest growing peptide therapeutics market by 2024.  

On the basis of application of peptide therapeutics, the global market has been segmented by indications such as peptide drugs for cancer therapeutics and metabolic disorders, for cardiovascular drug and devices to central nervous system ailments. Apart from these diseases peptide therapeutics have been applied for infections, respiratory disorders to hematological disorders. Of these, metabolic disorders, immunological and cancer are presently the class of disease that ranks in the massive share in the revenue of the global peptide therapeutics market. Over 300 companies are involved in developing more than 200 peptide based drugs in more than 300 oncology projects.

PNS Pharma report on the “Global Peptide Therapeutics Market” provides an in-depth analysis of the burgeoning peptide market. The report provides an accurate insight into the growth of the market over the last few years with special emphasis on growth trends, price analysis of products, therapy cost per patient, and sales analysis of peptide therapeutics, followed by vital factors that might impact the market during the forecast period. The report finally concludes with future projections regarding peptide therapeutics across various segments which clearly indicate it to be one of the leading markets of the future.  


“Global Peptide Therapeutics Market, Dosage, Price & Clinical Trials Insight 2024” Report Highlight:

 

  • Global Peptide Therapeutics Market Opportunity: More Than US$ 50 Billion
  • Cost Analysis & Market Insight into its Application
  • Dosage & Sales Analysis of Key Drugs
  • Global Peptide Drug Clinical Pipeline: 612 Drugs
  • Peptide Drug Application  by Indication
  • Global Peptide Pipeline by Indication, Company & Phase
  • Marketed Peptide Drugs: 101 Drugs
  • Clinical Trials Insight by Peptide Classification

 

Peptide based therapeutics are currently experiencing a renaissance in the global market with collective sales of more than US$ 20 Billion in 2017. Therapeutics such as Lantus, from Sanofi has recently managed to become a blockbuster peptide therapeutic with record sales of over US$ 8 Billion in 2017. Overall, the global peptide therapeutics market is expected to surpass US$ 50 Billion by 2024 from less than US$ 30 Billion in 2018. The overall market growth will be driven by the increasing research and development expenditure by pharmaceutical organizations along with rapid entry of multiple peptide based drug in the market. 

As of 2018, more than 100 approved peptide therapeutics for various clinical indications are commercially available in the global market. Additionally, a robust clinical pipeline currently has more than 100 type of therapeutics in late stage of clinical development with more than 200 types of therapeutics in pre-clinical stage.  

Epidemic increase in clinical indications such as obesity, type II diabetes along with complex disease like cancer are key driving factors of the global peptide therapeutics market. Involvement of global pharmaceutical giants in mass production of peptide therapeutics and impressive investment in their research and development in segments like oncology, genetic disorders, rare disease and autoimmune disease is further bound to make it one of the most active and lucrative market in the future.

Owing to the high prevalence of lifestyle disorders like type II diabetes and obesity, the US currently leads the global peptide therapeutics market by a significant margin; followed by the European Union. However, with the alarming increase in patient base, the Asia-Pacific region is anticipated to emerge as one of the fastest growing peptide therapeutics market by 2024.  

On the basis of application of peptide therapeutics, the global market has been segmented by indications such as peptide drugs for cancer therapeutics and metabolic disorders, for cardiovascular drug and devices to central nervous system ailments. Apart from these diseases peptide therapeutics have been applied for infections, respiratory disorders to hematological disorders. Of these, metabolic disorders, immunological and cancer are presently the class of disease that ranks in the massive share in the revenue of the global peptide therapeutics market. Over 300 companies are involved in developing more than 200 peptide based drugs in more than 300 oncology projects.

PNS Pharma report on the “Global Peptide Therapeutics Market” provides an in-depth analysis of the burgeoning peptide market. The report provides an accurate insight into the growth of the market over the last few years with special emphasis on growth trends, price analysis of products, therapy cost per patient, and sales analysis of peptide therapeutics, followed by vital factors that might impact the market during the forecast period. The report finally concludes with future projections regarding peptide therapeutics across various segments which clearly indicate it to be one of the leading markets of the future.  

1. Emergence of Peptide Therapeutics: New Growth Frontier For Pharmaceutical Industry

  1.1 Peptides as Drug Candidates

  1.2 Why Need for Peptide Therapeutics?

 

2. Cusp of Small Molecules & Proteins

  2.1 Peptides v/s Small Molecules

  2.2 Peptides v/s Protein Biologics

 

3. Fundamentals of Peptide Therapeutics

  3.1 Rational Design for Novel Peptides

  3.2 Aspects of Regulatory Approvals

 

4. Peptide Therapeutics – Cost Analysis & Market Insight into its Application

  4.1 Application of Peptides in Imaging

  4.2 Application of Peptides in Diseases

 

5. Peptide Therapeutics For Treatment of Metabolic Disorder

  5.1 Prologue to Metabolic Disorders

  5.2 Approved Peptide Drugs for Metabolic Disorders – Cost & Dosage Analysis

  5.3 Market of Metabolic Peptides

 

6. Peptide Therapeutics in Cancer – Drug Price & Therapy Cost Analysis

  6.1 Prologue to Cancer

  6.2 Dose & Price Analysis of Peptide Cancer Therapeutics

    6.2.1 Abralix

    6.2.2 Degarelix

    6.2.3 Octreotide

    6.2.4 Leuprolide

    6.2.5 Sipuleucel-T ( Provenge)

    6.2.6 Goserelin (Zoladex)

  6.3 Cancer Peptide Therapeutics – Sales Analysis

 

7. Peptide Therapeutics For Treatment of Cardiovascular Disease

  7.1 Prologue to Cardiovascular Diseases

  7.2 Approved Peptide Drugs in Cardiovascular Diseases

  7.3 Cardiac Peptide Therapeutics – Sales Analysis

 

8. Peptide Therapeutics For Treatment of HIV Infections

  8.1 Prologue to Infections

  8.2 Approved Peptide Therapeutics in Infections

  8.3 Anti-Infectious Peptides – Sales Analysis

 

9. Peptide Therapeutics For Treatment of CNS Disorders

  9.1 Prologue to CNS Disorders

  9.2 Neuropeptides Drug Delivery to CNS

  9.3 Future Market Potential

 

10. Global Peptide Therapeutics Market Current Scenario

  10.1 Overview

  10.2 Peptide Market by Application

 

11. Global Peptides Drug Clinical Pipeline Overview

  11.1 Cyclic Peptides

  11.2 Depsipeptides

  11.3 Dipeptides

  11.4 Glycopeptides

  11.5 Lipopeptides

  11.6 Natriuretic Peptides

  11.7 Neuropeptides

  11.8 Oligopeptides

  11.9 Opioid Peptides

  11.10 Peptides

  11.11 Multiple Peptides

 

12. Global Peptide Market by Route of Administration

  12.1 Current Trends in Route of Administration

  12.2 Current Trends over the Peptide Products

 

13. Global Peptide Market by Region

  13.1 North America

  13.2 Europe

  13.3 Asia


14. Global Peptide Drug Market Dynamics

  14.1 Favorable Parameters

  14.2 Challenges

 

15. Global Peptide Therapeutics Market Future Outlook

  15.1 Future Trends in Peptide Therapeutics

  15.2 Future Opportunities of Peptides Therapeutics

 

16. Cyclic Peptides Clinical Trials Insight by Phase, Indication & Company

  16.1 Preclinical till Preregistration

  16.2 Marketed

 

17. Depsipeptides Clinical Trials Insight by Phase, Indication & Company

  17.1 Preclinical till Preregistration

  17.2 Marketed

 

18. Dipeptides Clinical Trials Insight by Phase, Indication & Company

  18.1 Preclinical till Preregistration

  18.2 Marketed

 

19. Glycopeptides Clinical Trials Insight by Phase, Indication & Company

  19.1 Preclinical till Preregistration

  19.2 Marketed

 

20. Lipopeptides Clinical Trials Insight by Phase, Indication & Company

  20.1 Preclinical till Preregistration

 

21. Natriuretic Peptides Clinical Trials Insight by Phase, Indication & Company

  21.1 Preclinical till Preregistration

  21.2 Marketed

 

22. Neuropeptides Clinical Trials Insight by Phase, Indication & Company

  22.1 Preclinical till Preregistration

  22.2 Marketed

 

23. Oligopeptides Clinical Trials Insight by Phase, Indication & Company

  23.1 Preclinical till Preregistration

  23.2 Marketed

 

24. Opioid Peptides Clinical Trials Insight by Phase, Indication & Company

  24.1 Preclinical till Preregistration

  24.2 Marketed

 

25. Peptides Clinical Trials Insight by Phase, Indication & Company

  25.1 Preclinical till Preregistration

  25.2 Marketed

 

26. Multiple Peptides Clinical Trials Insight by Phase, Indication & Company

  26.1 Preclinical till Preregistration

  26.2 Marketed

 

27. Competitive Landscape

  27.1 Amgen

  27.2 Amylin Pharmaceuticals

  27.3 Apitope Technology

  27.4 BioPartners

  27.5 BiondVax Pharmaceuticals Ltd

  27.6 Boehringer Ingelheim

  27.7 Circassia

  27.8 Corden Pharma (Peptisyntha)

  27.9 Eli Lily

  27.10 Galena Biopharmaceuticals

  27.11 GlaxoSmithKline

  27.12 Hyperion Therapeutics

  27.13 ImmunoCellular Therapeutics

  27.14 Ipsen

  27.15 Lonza

  27.16 Merck

  27.17 NovoNordisk

  27.18 Par Pharmaceuticals

  27.19 PeptiDream

  27.20 Roche

  27.21 Sanofi

  27.22 Tarix Pharmaceuticals


Figure 2-1: Peptides as a Cusp of Small Molecule Drug & Proteins

Figure 2-2: Layout of Advantages of Peptide Drugs

Figure 3-1: Classification Based over the Sources of Peptide

Figure 3-2: Strategies for Screening of Novel peptides for Therapeutic Use

Figure 3-3: Methods for Generating Peptide Therapeutics at Large Scale

Figure 3-4: Whole General Concept of Manufacturing of Peptide Drugs

Figure 3-5: Process of Peptide Therapeutics FDA Approval Path

Figure 4-1: Global- Imaging Technology Market by Usage (%), 2018

Figure 4-2: Healthcare Imaging Market Share by Company (%), 2018

Figure 4-3: Diagrammatic Representation of the Peptidic Probe

Figure 4-4: Distribution of Therapeutic Drugs Approved by FDA by Chemical Species

Figure 4-5: Global - Peptide Therapeutics Market Size by Clinical Indications, 2018

Figure 5-1: Global - Prevalence of Metabolic Disorders by Region (%), 2018

Figure 5-2: Layout of Metabolic Syndrome Leading to Several Diseases

Figure 5-3: Global - Top 10 Countries with Diabetes Burden (Million), 2030

Figure 5-4: Global – Obesity in Women & Men by Region (Million), 2018

Figure 5-5: US– GLP-1 Agonist Drugs Comparative Cost Analysis (US$), 2018

Figure 5-6: Lantus – Monthly Cost Comparison by Country (US$), 2018

Figure 5-7: Global – Metabolic Peptide Market Size (%), 2018

Figure 6-1: Global - Cancer Cases per 100,000 People (Top 10), 2018

Figure 6-2: Abraxis - Dosage Analysis (Mg/Day)

Figure 6-3: Degarelix - Dose Analysis (Mg/Patient)

Figure 6-4: Degarelix - Price Analysis (US$/Injection Vial), 2018

Figure 6-5:  Degarelix-Monthly & Annual Treatment Cost Analysis (US$/Patient), 2018

Figure 6-6: Octerotide - Recommended Dosage for Carcinoid Tumor (Mcg/Patient)

Figure 6-7: Octreotide - Recommended Dosage for VIPOmas (Mcg/Patient)

Figure 6-8: Octreotide - Injectable Solution Price Analysis (US$/Mcg Vial), 2018

Figure 6-9: Leuprolide -Adult Dosage Analysis for Prostate Cancer by Month (Mg)

Figure 6-10: Leuprolide -Adult Dosage Analysis for Endometriosis in Women (Mg)

Figure 6-11: Provenge - Price Analysis (US$), 2018

Figure 6-12: Global - Cancer Peptide Therapeutics Market Size (%), 2018

Figure 6-13: US - Velcade Market Sales (US$ Million), 2018

Figure 6-14: Global – Estimated Velcade Sales (US$ Billion), 2018 - 2024

Figure 6-15: Global - Kyprolis Saless (US$ Billion), 2013 - 2017

Figure 6-16: Global & US - Zoladex Sales (US$ Million), 2017

Figure 7-1: Global - Cardiovascular Mortality (%), 2018

Figure 7-2: Cardiovascular Peptide Therapeutics - Cost Analysis (US$//Patient), 2018

Figure 7-3: Global - Angiomax Sales (US$ Million), 2018

Figure 7-4: Global - Integrilin Sales (US$ Million), 2016 & 2017

Figure 8-1: Global - Top 10 Leading Causes of Death

Figure 8-2: Global – Distribution of AIDS Affected Patients by Region (%), 2018

Figure 8-3: Fuzeon - Global Sales (US$ Millions), 2015 - 2017

Figure 9-1: US - Prevalence of Alzheimer’s disease (Million)

Figure 9-2: Alzheimer Disease Market Size (%), 2018

Figure 10-1: Global - Insulin Market Forecast (US$ Billion) 2018 - 2024

Figure 11-1: Global - Total Peptides Clinical Pipeline by Phase (%), 2018 till 2024

Figure 11-2: Global Total Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-3: Global Cyclic Peptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-4: Global Cyclic Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-5: Global Depsipeptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-6: Global Depsipeptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-7: Global Dipeptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-8: Global Dipeptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-9: Global Glycopeptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-10: Global Glycopeptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-11: Global Lipopeptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-12: Global Lipopeptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-13: Global Natriuretic Peptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-14: Global Natriuretic Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-15: Global Neuropeptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-16: Global Neuropeptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-17: Global Oligopeptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-18: Global Oligopeptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-19: Global Opioid Peptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-20: Global Opioid Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-21: Global Peptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-22: Global Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 11-23: Global Multiple Peptides Clinical Pipeline by Phase (%),2018 till 2024

Figure 11-24: Global Multiple Peptides Clinical Pipeline by Phase (Number), 2018 till 2024

Figure 12-1: Therapeutic Peptide Based Drugs over Route of Administration

Figure 14-1: Illustration of Peptide Therapeutics Market Drivers

Figure 14-2: Major Challenges Faced by the Peptide Therapeutics

Figure 15-1: Global – Estimated Future Peptide Therapeutics Market Size by Clinical Indication (%), 2024

Figure 15-2: Global - Cancer Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024

Figure 15-3: Global - Metabolic Disorders Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024

Figure 15-4: Global - Cardiovascular Peptide Therapeutic Market Forecast (US$ Billion), 2018 - 2024

Figure 15-5: Global - CNS, HIV & Infection Peptide Therapeutics Forecast (US$ Billion), 2018 - 2024

Figure 15-6: Future Trends of Peptide Therapeutics

Figure 15-7: Global - Peptide Therapeutics Market Forecast (US$ Billion), 2018 - 2024

 

 

 

List of Tables

 

Table 2-1: Comparative Analysis of Small Molecules & Peptide Drugs

Table 2-2: Comparative Differentiation between Peptide & Protein Drugs

Table 5-1: Major Approved GLP-1 Peptide Drugs for Metabolic Disorders

Table 5-2: Layout of Insulin & its Analogs Cost in US

Table 6-1: Approved Commercialized Peptide Cancer Drugs

Table 7-1: Approved Peptide Drugs for Cardiovascular Diseases

Table 8-1: Approved Drugs for Infections

Table 9-1: Brief Characterization of Some Neuroprotective Peptides

Table 9-2: Potential Targets for Peptide Based Therapies in CNS Disorders

Table 12-1: List of Approved Peptide Drugs Since 2000